We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Breath Test Can Detect Illness

By HospiMedica staff writers
Posted on 06 Dec 2004
A new test that detects free radicals released in an exhalation of breath can determine whether patients with heart transplants are showing signs of rejecting the new heart. More...
The test, called Heartsbreath, has been cleared for this use by the U.S. Food and Drug Administration (FDA).

The test is noninvasive and has no risks. The FDA said it might be used as an adjunct to biopsy. Menssana Research at the Enterprise Development Center, New Jersey Institute of Technology (Newark, USA), is commercializing the technology. In November 2004, the company was named second runner-up in the biotechnology and medical section of the annual technology innovation awards of The Wall Street Journal.

In a patented process, breath samples are imbedded in activated carbon, sealed in cigarette-sized steel cylinders and mailed to the laboratory for analysis. Menssana has identified distinct patterns made by more than 200 different volatiles organic compounds exhaled in every breath. These patterns vary with illness and can be used to diagnose a variety of diseases.

"Diabetics' breath smells fruity because of acetones, patients in kidney failure have breath that smells like urine, and liver disease and lung infections also have distinctive odors,” explained the inventor, Michael Phillips, M.D., clinical professor of medicine at New York Medical College (Vahalla, NY, USA).

The principle behind Dr. Phillips' research is oxidative stress. Disease is associated with an increase in free radicals, which damage the cell membrane, releasing the volatile organic compounds, some of which are ultimately exhaled. Dr. Phillips found a way to use activated charcoal to capture these compounds, concentrate them with intense heat, and then use gas chromatography to separate the compounds and mass spectrometry to identify them.

"It's completely safe, has virtually no false-negative results, and it's cheap,” Dr. Phillips added.




Related Links:
Menssana Research

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Heavy-Duty Wheelchair Scale
6495 Stationary
PACS Workstation
PaxeraView PRO
Autoclave
Advance
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.